Hetanshi Naik, PhD
- ASSISTANT PROFESSOR | Genetics and Genomic Sciences
- ASSISTANT PROFESSOR | Population Health Science and Policy
Research Topics:
Behavioral Health, Clinical Genomics, Education, Fabry Disease, Gene Therapy, Genetics, Genomics, Human Genetics and Genetic Disorders, Lysosomal Storage Diseases, Patient Centered Outcomes Research, Pharmacogenomics, PorphyriaDr. Hetanshi Naik is an Assistant Professor in the Departments of Genetics and Genomic Sciences and Population Health Science and Policy, Director of the Genetic Clinical Trials Office, and the Director of Clinical Research for the Master’s Program in Genetic Counseling.
Dr. Naik completed her Master’s in Genetic Counseling at the Icahn School of Medicine at Mount Sinai in 2010 and worked as a practicing genetic counselor in the Division of Medical Genetics and Genomics. She completed her PhD in Clinical Research in 2018 and joined the faculty at Mount Sinai in 2019.
Her clinical interests include Lysosomal Storage Diseases and the Porphyrias, while her research interests include developing clinical trial methodologies that are both scientifically rigorous and feasible in the rare disease setting, understanding the long-term psychosocial issues patients with rare diseases face, Patient Reported Outcomes (PROs) for rare diseases, and pharmacogenomic studies centered on assessing patient and provider knowledge.
She has been an investigator on, coordinated, and managed numerous industry sponsored and investigator initiated clinical research studies within the Department of Genetics and Genomic Sciences, and has served as the Project Manager of the NIH-funded national Porphyrias Consortium. As the Director of the Genetics Clinical Trial Office she helps physician-scientists develop and launch clinical research studies and innovative trials for genetic diseases.
Multi-Disciplinary Training Area
Genetics and Genomic Sciences [GGS]Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Naik during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Alnylam Pharmaceuticals; Disc Medicine
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.